EQT moves SHL Medical stake into long-term strategy fund

The sponsor's EQT VIII (2017 vintage) fund will exit its stake in the transaction, while family office ATHOS and other co-investors will join the new shareholding structure. 

Roger Samuelsson, SHL Medical's founder, will remain the majority shareholder.

EQT launched its Future fund, which has a EUR 4bn target, in October 2021. The fund has a 12-year life span with a three-year expansion and is still in the market, according to EQT's Q3 2022 report.

The GP said that SHL Medical has an ambitious growth strategy until 2023 and has outperformed its business plan since it acquired a 31.3% in January 2020. 

The company is working on new product launches while expanding its production footprint to North America and Europe, having upgraded its manufacturing and commercial capabilities under the first phase of EQT's ownership, the GP said in a statement. 

EQT made its second deal via the Future fund in March, taking a minority stake in two fruit genetic companies SNFL and IFG. 

Company
SHL Medical serves as a partner to global pharmaceutical and biotech companies in the development and production of medical autoinjectors. Autoinjectors are the preferred drug delivery solutions for highly complex biologic drugs and its biosimilar derivatives, said EQT. 

People
SHL – Roger Samuelsson (founder); Ulrich Faessler (CEO).
EQT – Rikke Kjær Nielsen, (partner, EQT Future).
ATHOS – Wolfgang Essler (general manager).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Portfolio management
• Exits
• Healthcare
• GPs
• EQT
• Switzerland